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Psoriasis is a common chronic inﬂammatory cutaneous disease, while primary cutaneous CD30þ
anaplastic large-cell lymphoma (PC-ALCL) is a rare T-cell lymphoma which always has an excellent
prognosis, although multifocal PC-ALCL tends to relapse after systemic chemotherapy. Psoriasis
associated with PC-ALCL is exceptionally rare. We report a 29-year-old Chinese female with a 5-year
history of psoriasis treated with Chinese herbs alone, who was referred to our institution with
a tumor on the left clavicular region for 1 year and another one on the left palm for 2 months. Skin
biopsies of both lesions showed diffuse inﬁltration of tumor cells, composed of large atypical cells
with marked nuclear pleomorphism, prominent nucleoli, and eosinophilic cytoplasm. Large numbers
of neutrophilic inﬁltrations were also noted in the lesion. Immunostaining revealed the lesion to be
positive for CD30, vimentin, CD45, and CD68, and weakly positive for epithelial membrane antigen,
but negative for anaplastic lymphoma receptor tyrosine kinase. The patient was diagnosed to have
psoriasis associated with PC-ALCL; she died 18 months after the ﬁnal diagnosis with unknown cause.
We consider that immune dysregulation and/or Chinese herbs may play roles in the development of
the present PC-ALCL.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Psoriasis is a common, chronic inﬂammatory disease that always
involves the skin and occasionally, the joints. Although it can
occur at any age, psoriasis most commonly afﬂicts the adult
population.1 It has serious impacts on health-related quality of
life and increases health care costs.1,2 Furthermore, psoriasis has
been thought to be associated with an increased risk of cancer,
including skin cancer and lymphoma,1e7 due to its dysregulated
immune function and the potential carcinogenicity of therapeutic
agents, or a combination of these factors.2,8 Moreover, psoriasis
associated with primary cutaneous CD30þ anaplastic large cell
lymphoma (PC-ALCL) in the therapeutic course of cyclosporine
has been previously reported.7
We describe a psoriasis patient who developed PC-ALCL, and to
our knowledge, such a condition is exceptionally rare.gy, Huangpu Hospital of The
ngzhou, China. Tel.: þ86 20
).
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A 29-year-old Chinese female had been affected by psoriasis vul-
garis since 2004, which was conﬁrmed by biopsy (Figure 1). She
had intermittently received oral treatment of traditional Chinese
herbs alone (no details) in the community clinic since then. In
October 2007, she noticed an asymptomatic reddish painless
papule on her left clavicular region, which gradually enlarged and
grew to be a tumor with surface erosion. In April 2008, she was
started on a low-dose methotrexate therapy (10 mg/week) because
of severe psoriasic lesions; this was carried out for 6 months and
resulted in signiﬁcant improvements for psoriatic lesions but poor
response for the tumor. In August 2008, during her anti-psoriasic
therapeutic course, another red papule appeared on her left palm
which began to swell. Both tumors did not respond to oral or topical
antibiotics, and topical steroids.
She had never received any other medications except the ther-
apies mentioned above. No other medical history includingmycosis
fungoides and lymphomatoid papulosis (LyP) was reported, and no
family members were similarly affected. The patient denied pain,
pruritus, weight loss, or any other associated symptoms since the
initial presentation of tumor.n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 There is epidermal hyperplasia with long, test-tube-shaped rete ridges and
thinning over the dermal papillae. The granular layer is absent, and there is overlying
parakeratosis. Munro microabscesses are present in the stratum corneum. There is
a perivascular mononuclear cell inﬁltrate. (Hematoxylin and eosin, original magniﬁ-
cation, 150.)
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10  9 cm in size on the left distal clavicular region, which was soft
and painless with ulcerated surface and sero-sanguinous discharge
(Figure 2A). The tumor was not attached to the surrounding tissue.
Another tumor, measuring 7  5 cm, was located on the thenar
margin of her left palm (Figure 2B). There was no regional
lymphadenopathy. Chest X-ray (Figure 3A) and B-ultrasound for
abdomen and pelvis showed no systemic or nodal involvement
(Figure 3B), and retroperitoneal lymph nodes were not observed.
Laboratory work-ups showed normal urinalysis, complete blood
count, and serum chemistries. Peripheral smear revealed no atyp-
ical lymphocytes.
Biopsies taken from both lesions showed similar features:
diffuse tumor cells inﬁltration. The tumor was composed of
large atypical cells with marked nuclear pleomorphism, prom-
inent nucleoli, and eosinophilic cytoplasm. Large numbers of
neutrophilic inﬁltrations were also noted in the lesion
(Figures 4A and 4B). Immunohistochemical staining showed
that the tumor cells were positive for CD30 (>75%, Figure 4C),
vimentin, CD68, and CD45; weakly positive for epithelial
membrane antigen (EMA) (Figure 4D), CD20; but negative for
CD3, CD4, CD8, anaplastic lymphoma receptor tyrosine kinase
(ALK), actin, myoglobin, CK5/6, CK8/18, CD56, CD79a, UCHL1, S-
100, and HMB-45.
The tumors were diagnosed as PC-ALCL. Because of ﬁnancial
constraints, the patient gave up any medical therapies and died 18Figure 2 Reddish-violet cutaneous tumors on (A) left distal clamonths after the ﬁnal diagnosis. The patient was free from psoriasis
at her last visit and at the time of death. The cause of death
remained unknown.
Discussion
Primary cutaneous CD30-positive T-cell lymphoproliferative
disorders include PC-ALCL, LyP, and other miscellaneous entities.9
Clinically, both PC-ALCL and LyP present with varied manifesta-
tions, leading to difﬁculty in diagnosis; however, some of LyP may
progress to PC-ALCL.10 The tumors reported here showed positive
for CD30 in majority of the cells and positive for EMA, but negative
for ALK. Based on the history, clinical appearance, pathologic
features, and immunomarkers, there was no doubt about the
diagnosis of cutaneous CD30þ ALCL in the present case. As both
lesions showed the same pathologic features, they were considered
to have the same origin. Although the present case was weakly
positive for EMA, which is frequently expressed in systemic
lymphoma and cutaneous involvement secondary to systemic
ALCL, positive EMA may also be rarely stained in PC-ALCL as
a previous report demonstrated that one out of 10 PC-ALCL cases
expressed EMA,11 and in multiple myeloma associated with PC-
ALCL as well.12 ALK expression is exceptionally rare and probably
entirely absent in PC-ALCL.13 Considering that the patient lacked
peripheral and/or abdominal lymphadenopathy, systemic involve-
ment, B symptoms, and was negative for ALK, we considered her
cutaneous lesions to be primary tumor rather than systemic or
secondary.
It is clear that medications for psoriasis may prove carcinogenic
for patients. For example, systemic therapies such as methotrexate,
cyclosporine, and mycophenolate mofetil increase the risk of lym-
phoproliferative disorders1; long-term psoralen combined with
ultraviolet A therapy is associated with an increased risk of basal
cell carcinoma and melanoma,1 but UVB seems to have no such
associations.1 On the other hand, patients with psoriasis have
higher risks for malignancy compared to the general population.1,2
The present patient had a 5-year history of psoriasis before her PC-
ALCL, and had been treated only with traditional Chinese herbs. As
some Chinese herbs have been demonstrated to have carcinoge-
nicity, we considered that immune dysfunction and/or traditional
Chinese herbs may play important roles in the development of the
tumors. Considering the respective frequencies of the two entities,
we also could not exclude the possibility that their associationsmay
be fortuitous. We did not consider that methotrexate played
a carcinogenic role, since the initial lesion appeared before the
patient was treated with methotrexate.
PC-ALCL usually occurs in the elderly, has male predilection, and
has a favorable prognosis with spontaneous regression in somevicular region and (B) the thenar margin of the left palm.
Figure 3 (A) Chest X-ray shows clear lung ﬁelds except for a shadow on the left shoulder. (B) Sonography reveals a clear liver.
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children and adolescents, and has worse prognosis.7,9 Interestingly,
the patient was only 28 years old when her initial ALCL lesion
appeared, and had a poor prognosis even though her cause of death
was unknown.
PC-ALCL patients with multifocal skin lesions and with involve-
ment of regional lymph nodes show a similar prognosis to those
with only skin lesions. In localized forms and solitary lesions, local
radiotherapy, simple surgical excision, low-dose methotrexate,14,15
and interferon alone or in association with bexarotene are the
mainstay therapeutic options.9 In patients with large tumor
burden, rapid progression of cutaneous lesion, and extracutaneous
involvement, systemic chemotherapy should be recommended.9Figure 4 (A,B) Skin biopsy shows diffuse tumor cell inﬁltration, composed of large atyp
cytoplasm (hematoxylin and eosin; original magniﬁcation: A 100, B 400). The tumo
magniﬁcation, 40) and (D) EMA (400).However, the initial lesion of the present patient failed to
respond to the previous anti-psoriasic therapy with low-dose
methotrexate, and a second lesion even developed during the
therapeutic course. The reason for such a response remains
unknown. It also suggested that low-dose methotrexate may not
always be a good option for PC-ALCL.
Our case is notable for psoriasis associated with PC-ALCL,
multiple tumor lesions as well as EMA-positive immunoreactivity
of the tumor cells, and having survived for only 30months since the
initial lesion appeared. It is also notable that her tumors had poor
response to low-dose methotrexate. The poor prognosis showed
that untreated PC-ALCL in adolescents may not always have
favorable prognoses.ical cells with marked nuclear pleomorphism, prominent nucleoli, and eosinophilic
r cells are positively stained for (C) CD30 (immunohistochemical staining; original
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